Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15871710 | 0.86 | CYP2D6 (0.38) | CYP2D6SMN1; SMN2TSHRHSD11B1MMP1 | |
| SCHEMBL24010012 | 0.80 | TSHR (0.37) | CYP2D6SMN1; SMN2TSHR | |
| SCHEMBL26400792 | 0.76 | CYP2D6 (0.36) | CYP2D6SMN1; SMN2MMP1MMP9MMP13 | |
| SCHEMBL24009185 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2HSD11B1KDM4E | |
| SCHEMBL24308819 | 0.74 | TSHR (0.43) | CYP2D6SMN1; SMN2TSHRHSD11B1KDM4E | |
| SCHEMBL15100017 | 0.71 | TSHR (0.40) | SMN1; SMN2TSHRHSD11B1KDM4EGAA | |
| SCHEMBL24009201 | 0.71 | — | — | |
| SCHEMBL15871711 | 0.71 | CYP2D6 (0.66) | CYP2D6SMN1; SMN2TSHRCYP3A4CYP2C9 | |
| SCHEMBL20962687 | 0.70 | TSHR (0.39) | SMN1; SMN2TSHRHSD11B1KDM4EGAA | |
| SCHEMBL15113488 | 0.70 | TSHR (0.39) | SMN1; SMN2TSHRHSD11B1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | CYP2D6 2442/4885SMN1; SMN2 820/4885TSHR 4083/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | CYP2D6 2442/4885SMN1; SMN2 820/4885TSHR 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.